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The transcriptional coactivator Yes-associated pro-
tein (YAP) plays an important role in organ-size con-
trol and tumorigenesis. However, how Yap gene
expression is regulated remains unknown. This study
shows that the Ets family member GABP binds to the
Yap promoter and activates YAP transcription. The
depletion of GABP downregulates YAP, resulting in
a G1/S cell-cycle block and increased cell death,
both of which are substantially rescued by reconsti-
tuting YAP. GABP can be inactivated by oxidative
mechanisms, and acetaminophen-induced gluta-
thione depletion inhibits GABP transcriptional activ-
ity and depletes YAP. In contrast, activating YAP by
deleting Mst1/Mst2 strongly protects against acet-
aminophen-induced liver injury. Similar to its effects
on YAP, Hippo signaling inhibits GABP transcrip-
tional activity through several mechanisms. In human
liver cancers, enhanced YAP expression is corre-
lated with increased nuclear expression of GABP.
Therefore, we conclude that GABP is an activator
of Yap gene expression and a potential therapeutic
target for cancers driven by YAP.
INTRODUCTION
The Hippo pathway is an evolutionarily conserved protein kinase
cascade that negatively regulates the oncogenic transcriptional
coactivator Yes-associated protein (YAP) and its paralog, TAZ
(Pan, 2010; Zhao et al., 2011). In the canonical Hippo pathway,
the kinase core consists of the Ste20-like kinases Mst1/Mst2
(Hippo in Drosophila), which in association with the WW-domainCscaffolding protein WW45 (Salvador) phosphorylate the nuclear
Dbf2-related (NDR) family kinases Lats1/2 (Warts) and the non-
catalytic protein Mob1A/B (Mats). Phospho-Mob1A/B then
binds to and promotes the autophosphorylation and activation
of Warts/Lats, which in turn phosphorylates YAP (yorkie; Yki),
resulting in its binding to 14-3-3. This interaction promotes
YAP/Yki nuclear exit, thereby inhibiting YAP/Yki function. Intra-
nuclear YAP/Yki promotes cell proliferation and inhibits cell
death through the Scalloped/TEAD transcription factor(s) (Lamar
et al., 2012; Liu-Chittenden et al., 2012; Zhao et al., 2008).
The loss of any component of the kinase core results in a YAP-
dependent increase in proliferation, resistance to apoptosis, and
massive organ overgrowth (Zhou et al., 2009, 2011). Similarly,
overexpression of a ‘‘Hippo-resistant’’ YAP mutant leads to the
expansion of progenitor cells and cancer development in multi-
ple organs (Camargo et al., 2007). Thus, the central function of
the Hippo pathway is to inhibit the function of YAP/Yki (Sudol
et al., 2012) to restrain organ overgrowth.
YAP is a candidate oncogene in humans because YAP protein
expression and/or nuclear localization levels are elevated in
many human cancers, and the 11q22 amplicon, which encom-
passes the Yap gene, is frequently observed in human cancers
(Overholtzer et al., 2006; Zender et al., 2006). This and other
findings indicate that regulation of YAP’s protein level is a very
important aspect of its oncogenic function. Although numerous
studies have investigated YAP phosphorylation, degradation,
and nuclear localization (Basu et al., 2003; Huang et al., 2005;
Levy et al., 2008; Zhao et al., 2007), far fewer studies have
addressed the regulation of YAP expression. Previous research
has implicated c-Jun (Danovi et al., 2008), b-catenin (Konsavage
et al., 2012), andmicroRNA-375 (Liu et al., 2010) in the regulation
of Yap gene expression, but the timing, context, and impact of
their actions remain unclear. Thus, how Yap gene expression is
regulated during normal development, organ size control, and
cancer development remains to be fully understood.ell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authors 1663
When we examined which transcription factors affect the
regulation of Yap gene expression under physiological condi-
tions, we identified an Ets family transcription factor called
GA-binding protein (GABP; LaMarco and McKnight, 1989),
also known as nuclear respiratory factor 2 (NRF-2; Virbasius
et al., 1993) or adenovirus E4 transcription factor 1 (E4TF-1;
Watanabe et al., 1993). GABP binds specifically to multiple
Ets-binding sequences (GGAAG) that are present in the Yap
promoter and activates it. Among the more than two dozen
mammalian Ets factors in this family, GABP is the only obligate
multimeric complex composed of two distinct and unrelated
proteins, GABPa and GABPb (LaMarco et al., 1991; Thompson
et al., 1991). GABPa mediates DNA binding through its Ets
domain but lacks transcriptional activity. GABPb contains the
transcription activation domain, a nuclear localization determi-
nant, and four ankyrin repeats that mediate its heterodi-
merization with GABPa. GABP is ubiquitously expressed and
regulates lineage-restricted genes, ribosomal and mitochon-
drial genes, and genes that control cellular growth (Yu et al.,
2011, 2012).
As with Yap (Morin-Kensicki et al., 2006), homozygous dele-
tion of the Gabpa gene in mice results in early embryonic
lethality (Xue et al., 2008), indicating that GABPa is critically
important for organ development. The transcriptional activity
of the GABP complex is regulated by its redox state through
the oxidation of one or more cysteine residues in the DNA-
binding and dimerization domains of the GABPa subunit (Chine-
nov et al., 1998). Treatment of 3T3 cells with the glutathione
(GSH)-depleting agent pro-oxidant diethyl maleate (DEM)
almost completely inhibits GABPa DNA-binding activity and
the dimerization of GABPa/GABPb in nuclear extracts. In
contrast, the antioxidant N-acetylcysteine (NAC) substantially
protects GABP DNA-binding activity from DEM-mediated inhibi-
tion (Martin et al., 1996).
In addition, in vitro studies have demonstrated that both sub-
units of GABPa/b can be phosphorylated directly by mitogen-
activated protein kinases (MAPKs; Flory et al., 1996). The threo-
nine at position 280 of GABPa and the serine 170 and threonine
180 of GABPbwere identified as the major phosphorylation sites
in vitro and in vivo (Fromm and Burden, 2001). The activity of
several Ets transcription factors is augmented by phosphoryla-
tion (Wasylyk et al., 1998), and the transcriptional activity of
GABP may also regulated by phosphorylation. Nevertheless,
the physiological context and functional effect of GABP phos-
phorylation on its transcriptional activity remain to be elucidated.
In this study, we demonstrate that the Ets family transcription
factor GABPa/GABPb is required for YAP expression in vitro and
in vivo, and that YAP is an important effector downstream of
GABP for cell survival and cell-cycle progression. Moreover,
we show that YAP, through its ability to promote the expression
of an antioxidant transcriptional program, exerts positive feed-
back regulation on GABP. Finally, we show that the Hippo
pathway, in addition to directly inhibiting YAP, also inhibits
GABP function through both phosphorylation and direct pro-
tein-protein interaction. Taken together, these results suggest
that GABP is a central regulator of Yap gene transcription, and
that similarly to YAP, GABP is negatively regulated by the Hippo
kinase pathway.1664 Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The AuthorsRESULTS
GABP Is a Physiologic Activator of the Yap Promoter
To identify transcription factors that regulate the Yap promoter,
we generated 50-biotinylated 3.6, 2.6, 2, 1, or 0.36 kb DNA frag-
ments corresponding to Yap promoter sequences upstream of
the ATG start codon (Figure S1A; Table S1). Each of these frag-
ments was incubated with mouse liver lysates, followed by pull-
down with streptavidin-agarose beads. A protein band near 45
kD (Figure S1A) was identified as GABPb by mass spectrometry.
Although GAPBb contains a transcriptional activation domain, it
cannot bind directly to DNA and must form a heterodimer with
the Ets-domain protein GABPa to do so. Therefore, we analyzed
the Yap promoter pull-down samples for GABPa by immunoblot-
ting, and confirmed that both GABPb and GABPa were present
in the Yap promoter pull-down samples (Figure S1B). DNA
sequence analysis of the Yap promoter showed that it contains
16 GGAAG sequences. This motif is an Ets family transcription
factor binding site (EBS) and is bound by GABP (Figure 1A).
Next, we sought to determine whether GABPa/GABPb binds
to the Yap promoter. We performed electrophoretic mobility shift
assay (EMSA) gel shift experiments using HeLa cell nuclear
extracts and biotin-labeled DNA probes corresponding to seg-
ments of the Yap promoter that contain the EBS (Table S1). As
visualized by EMSA, the addition of these probes to HeLa
nuclear extracts resulted in a pair of upshifted bands, suggestive
of GABPa/b dimers and a2b2 tetramers, and these bands were
further upshifted upon addition of the anti-GABPa antibody (Fig-
ure 1B). Chromatin immunoprecipitation (ChIP) assays in HeLa
or primary mouse hepatocyte extracts using the anti-GABPa
antibody and PCR primers specific for the Yap promoter
indicated that endogenous GABPa is associated with the Yap
promoter in vivo (Figure 1C; Table S1).
To determine whether the GABPa/GABPb and EBS sequence
are both required for the transcriptional activity of the Yap pro-
moter, we constructed a Yap promoter truncation series contain-
ing different GABPa binding sites fused upstream of a luciferase
reporter (Luc) and cotransfected these constructs into 293T cells
with GABPa, GABPb1L, GABPa + GABPb1L, or empty vector
(Figure 1D). The Yap promoter-driven luciferase activity of the
reporter plasmid was dramatically increased when it was
cotransfected with GABPa +GABPb1L compared with an empty
vector. In contrast, only a slight increase in luciferase activity was
observed when YAP-Luc was cotransfected with GABPa or
GABPb1L alone, which may reflect the heterodimerization of
the transfected GABP subunit with the endogenous GABPb or
GABPa. Moreover, the level of luciferase induction correlated
with the number of EBS sequences on the YAP-Luc reporter,
although the luciferase activity of YAP3600-Luc was slightly
lower than that of YAP2600-Luc (Figure 1D).
We also examined the effect of individual EBSs on GABPa/
GABPb1L-driven luciferase expression (Figure S1C). Deletion
of the EBSs between 67 and +70 from the YAP2600-luciferase
construct resulted in a modest decrease in luciferase activity,
whereas deletion of the EBS at +697 increased luciferase activity
to comparable levels. Overall, no single site had a dominant
contribution toward the reporter gene expression. The 67
and +70 sites, each of which contains two adjacent EBSs,
Figure 1. GABP Acts on the Mouse Yap Promoter In Vitro and In Vivo
(A) Multiple EBSs (GGAAG) are found in the Yap promoter region and are notably present in tandem repeats.
(B) EMSA and supershift analysis of the binding specificities of GABPa on the EBS of the Yap promoter. EMSA experiments were performed using two different
biotinylated probes (the sequences are presented in Table S1) with no nuclear extracts (a), HeLa cell nuclear extracts (b), or HeLa cell nuclear extracts that were
predepleted with anti-GABPa antibodies (c). The a2b2 tetramers and a/b dimers are indicated on the left. The supershift assay was performed by directly adding
anti-GABPa antibodies to the assay (d). The supershifted bands are indicated on the right side.
(C) The ChIP assay shows that GABPa binds to the Yap promoter in HeLa cells and in primary mouse hepatocytes.
(D) GABPa/b1 enhances the luciferase activity driven by the 50 flanking regions of the mouse Yap gene. The firefly luciferase activity was normalized against the
Renilla luciferase activity and is presented as the level relative to the normalized activity obtained with pGL3-YAP362-Luc cotransfected with an empty vector.
(E) In contrast to GABPb1S or GABPb2, GABPb1L cooperates with GABPa, resulting in the highest Yap promoter-driven luciferase activity.
(F) Overexpression of GABPa increases endogenous YAP expression in 293T cells.
The data are representative of at least three independent experiments. Error bars represent the SD; n = 3; ***p < 0.001. The p values refer to comparisons between
samples transfected with GABPa+b and with control vector. See also Figure S1.were equally important for luciferase expression from YAP362-
Luc. The deletion of either of the two adjacent EBSs reduced
luciferase activity by half, and the deletion of both resulted in
total abolition of luciferase activity (Figure S1D). Therefore,
GABP binds to multiple EBS sequences on the Yap promoter
and upregulates YAP transcriptional activity.CThe GABPa/b1L Complex Is the Most Effective Ets
Family Transcription Factor for Activation of the Yap
Promoter
Each of the three isoforms of the GABPb subunit—GABPb1L,
GABPb1S, and GABPb2—can associate with GABPa to form
the functional heterodimeric transcription factor GABPa/b. Theell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authors 1665
Figure 2. Cell-Cycle Arrest and Cell Apoptosis Resulting from the Knockdown of GABP Can Be Rescued or Prevented by YAP
Overexpression
(A and B) Doxycycline-induced knockdown of GABPa or GABPb dramatically decreases the protein levels (A) and transcript levels (B) of Skp2 and YAP.
(C and D) HepG2 cells were cotransfected with either GABPa shRNA-RFP or control shRNAs and either GFP-YAP or the control vector. At 72 hr
posttransfection, flow cytometry analysis was performed with Annexin V/DAPI staining (C) or bromodeoxyuridine (BrdU)/DAPI staining (D). GFP+RFP+ cells
were gated and plotted as indicated. The knockdown of GABPa enhances the early apoptosis (AnnexinV+DAPI) and late apoptosis (AnnexinV+DAPI+) of
HepG2 cells, whereas the overexpression of YAP restores cell survival to normal levels (C). The knockdown of GABPa induces an increase in the
G1 phase (bottom left quadrant) and a decrease in S phase (top quadrant) cells, whereas the overexpression of GFP-YAP restores the cell cycle to normal
levels (D).
(legend continued on next page)
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GABPb1L and GABPb1S isoforms are both encoded by the
Gabpb1 gene and have identical 332 amino-terminal domains,
but differ in their C-terminal regions due to differential messenger
RNA (mRNA) splicing. The two b1 isoforms heterodimerize with
GABPa with similar affinities (Suzuki et al., 1998). GABPb1L
has a longer C-terminal tail (50 amino acids), which contains a
leucine zipper-like domain that enables the formation of
GABPb1L homodimers and a2b2 GABP tetramers when two
Ets motifs are adjacent or brought into proximity (Sawada
et al., 1994). In contrast, the C terminus of GABPb1S contains
15 amino acids, lacks the C-terminal leucine zipper-like structure
of GABPb1L, and cannot form b-b dimers or a2b2 tetramers.
GABPb2, encoded by Gabpb2, shares an 87% identity with
GABPb1 and can form both GABPb2 homodimers and hetero-
dimers with GABPb1L. Therefore, we compared the activity of
YAP2600-Luc when coexpressed with GABPa alone or with
each of the three isoforms of GABPb (Figure 1E).
Each heterodimer resulted in stronger luciferase expression
thanGABPa alone. Among the heterodimers, GABPa+GABPb1L
resulted in the highest luciferase activity, GABPa+GABPb1S
showed the lowest activity, and GABPa+GABPb2 showed an in-
termediate level of activity (Figure 1E). Thus, GABPa+GABPb1L,
perhaps through its ability to form an a2b2 tetramer and bind to
adjacent EBSs (such as the 67 or +70 sites), enables the most
robust activation of the Yap promoter. The overexpression of
GABPa or GABPa+GABPb1L greatly increased the expression
of endogenous YAP in 293T cells, whereas GABPb1L alone did
not increase YAP expression (Figure 1F). This result suggests
that in 293T cells, endogenous GABPb may be present in
amounts sufficient to engage the transfected GABPa, thereby
forming active heterodimers.
GABP cooperates with other transcription factors, such as
P300, Esrra, PGC1a, YY1, and C/EBPb, to activate gene expres-
sion (Hock and Kralli, 2009). The coexpression of P300, Esrra,
PGC1a, YY1, or C/EBPb with YAP2600-Luc did not stimulate
luciferase expression, and their coexpression with GABPa/b1L
failed to enhance GABP-stimulated luciferase activity from
YAP2600-Luc. Only C/EBPb enhanced GABP-stimulated
YAP2600-Luc luciferase activity, by 30% (Figure S1E).
The Ets family of proteins, which is identified by its highly
conserved DNA-binding domain, the ETS domain, is one of the
largest families of transcription factors (Hollenhorst et al.,
2011). Because there are 16 putative EBS sequence sites
upstream of the YAP coding sequences (Figure 1A), we investi-
gated whether any Ets family transcription factors other than
GABP could stimulate Yap promoter activity. In addition to
GABPa and GABPb1L, we obtained complementary DNAs
(cDNAs) corresponding to 17 Ets family members (Figure S1F)
and generated Myc-tagged expression constructs for each
family member. The YAP2600-Luc construct was cotransfected
with each of these cDNA constructs, and protein expression was
verified by immunoblotting using an anti-Myc antibody (Fig-(E) Levels of GABPa, GABPb, YAP, Skp2, PCNA, pMob, and b-actin expression i
with the indicated antibodies.
(F and G) Mice injected with an adenovirus expressing GABPa and GABPb. The
The liver mass was weighed and the results are expressed as a bar graph (G).
The data are representative of at least three independent experiments. *p < 0.05;
Cure S1G). The luciferase assay results showed that only
GABPa/b1L resulted in a significant increase in YAP2600-Luc
luciferase activity (10-fold), and none of the other Ets family
members examined significantly enhanced the Yap promoter
activity (Figure S1H). These results suggest that within the Ets
family, GABPa/b1L exhibits considerable specificity as a regu-
lator of Yap promoter activation and transcription.
GABP Is Required for the Expression of YAP, and YAP Is
an Important Downstream Effector of GABP
After serum starvation, GABPa can be induced in cells by the
addition of serum (Yang et al., 2007). We demonstrated that
the level of GABPa, but not GABPb, increased progressively
after the readdition of serum to serum-deprived murine embry-
onic fibroblasts (MEFs), and the abundance of YAP increased
in parallel (Figure S2A). Quantitative PCR (qPCR) assays demon-
strated that the induction of GABPa and YAP proteins by serum
was accompanied by an increase in their respective mRNA
levels (Figure S2B). The expression of the E3 ligase protein
Skp2, which is encoded by a known transcriptional target of
GABP (Yang et al., 2007), was also enhanced by the readdition
of serum, but the expression of the cdk inhibitor protein P21, a
substrate of Skp2, was concomitantly decreased (Figure S2A).
To determine whether GABP is required for the expression of
endogenous YAP, we examined the effect of small hairpin RNA
(shRNA)-induced depletion of GABPa or GABPb on the abun-
dance of endogenous YAP in HepG2 cells. Although the deple-
tion of GABPa (Figure 2A, left) or GABPb (Figure 2A, right)
mRNAs did not alter the abundance of the other GABP mRNAs
(Figure S2A), the depletion of either GABP subunit substantially
reduced YAP andSkp2mRNA (Figure 2B) and protein (Figure 2A)
levels.
Previous studies suggested that GABP is required for cell-
cycle progression and may regulate cell survival (Yang et al.,
2007). Consistent with this view, the shRNA-induced depletion
of GABPa in HepG2 cells resulted in an increased number of
apoptotic cells (Figure 2C) and cells accumulating in G0/G1,
but fewer cells in S phase (Figure 2D). The cotransfection of
YAP cDNA and GABPa shRNA markedly reduced the number
of apoptotic cells (Figure 2C) and partially rescued the G1/S
block (Figure 2D). The inhibitory effect of GABPa or GABPbL1
depletion on colony formation was also significantly ameliorated
by the coexpression of YAP (Figures S2C and S2D). These
results provide further evidence that YAP is a downstream target
of GABP, and indicate that the positive effect of GABP on cell-
cycle progression and cell survival is achieved, at least in part,
through YAP.
GABP may promote cell-cycle progression, in part by
increasing YAP and Skp2 expression, during posthepatectomy
liver regeneration. Within several days after a two-thirds hepa-
tectomy, the remaining liver cells proliferated synchronously
to restore liver mass and function. Liver cell proliferation, asn regenerating livers after hepatectomies were determined by immunoblotting
YAP expression level was determined by immunoblotting the liver samples (F).
**p < 0.01; ***p < 0.001. Error bars represent the SD; n = 3. See also Figure S2.
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indicated by an increase in the cell proliferation marker prolifer-
ating cell nuclear antigen (PCNA), was not evident at 24 hr but
reached significant levels at 36 hr after resection (Figure 2E). In
contrast, the expression levels of GABP and its targets, YAP
and Skp2, increased within 24 hr after the hepatectomy, before
the onset of hepatocyte proliferation, and remained elevated
for 72 hr (Figures 2E and S2E). Furthermore, mice injected with
an adenovirus expressing GABPa and GABPb showed
increased YAP expression (Figure 2F), enhanced hepatocyte
proliferation (Figure S2F), and enlarged liver mass (Figure 2G).
The ability of GABP overexpression to drive hepatocyte prolifer-
ation strongly supports the hypothesis that the upregulation of
GABP (and YAP) expression that occurs early during posthepa-
tectomy liver regeneration contributes to hepatocyte prolifera-
tion and liver enlargement.
GSH Depletion Inhibits GABP-Dependent YAP
Expression
The transcriptional activity of GABP is regulated by oxidation/
reduction both in vitro and in vivo (Martin et al., 1996). pro-
oxidant conditions, such as treatment with the GSH-depleting
agent DEM, do not change the protein level of GABP but inhibit
its ability to bind DNA due to the oxidation of GABPa cysteine
residues (Cys388 and Cys401). In addition, oxidation of GABPa
Cys421 inhibits the heterodimerization of GABPa/GABPb,
thereby inhibiting GABP-dependent gene expression (Chinenov
et al., 1998). To determinewhether theGABP-driven activation of
the Yap promoter driven is also affected by pro-oxidant treat-
ment, HeLa cells that were transfected with YAP2600-Luc and
either GABPa+GABPb1L or control vector were treated with
DEM with or without the antioxidant NAC, a precursor of GSH
synthesis. Treatment with DEM alone resulted in a dramatic
decrease in the GABP-stimulated YAP2600-Luc luciferase activ-
ity, which was partially restored by combined treatment with
DEM plus NAC. However, NAC alone had a minimal effect
(Figure 3A).
We confirmed that DEM treatment causes a substantial
decrease in the ratio of reduced GSH to oxidized GSH (GSH/
GSSG; Figure 3B). Treatment of HepG2 cells (Figure 3C) or
primary mouse hepatocytes (Figure S3A) with DEM resulted in
a progressive decrease in the protein levels of YAP, the trans-
criptional target of GABP, and Skp2 and cMyc, which are tran-
scriptional targets of YAP. This effect was observed markedly at
24 hr, although the GABP protein subunit levels were not
reduced in either cell type. Similar to results for YAP2600-Luc
transcriptional activity (Figure 3A), combined treatment with
NAC plus DEM restored the protein levels of YAP, Skp2, and
cMyc, which were downregulated by treatment with DEM alone
(Figures 3C and S3A). Real-time PCR analysis suggested that
the reduced YAP and Skp2 protein levels in DEM-treated sam-
ples were accompanied by reduced mRNA levels. The mRNA
level of another YAP transcriptional target, CTGF (Zhao
et al., 2008), was also reduced by DEM, whereas the mRNA
levels of the GABP subunits were not significantly altered
(Figure S3B).
Immunofluorescence staining of HeLa cells showed that un-
der normal culture conditions, GABPa was localized exclusively
in the nucleus, but upon DEM treatment, a portion translocated1668 Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authorsto the cytoplasm (Figure 3D). In contrast, GABPb was found in
both the cytoplasm (as bright dots) and the nucleus, and its
distribution was not affected by DEM treatment (Figure 3D).
DEM treatment resulted in cell-cycle arrest and enhanced cell
death, both of which could be partially rescued by NAC treat-
ment or by increasing YAP expression (Figure 3E). An MTT cell
proliferation assay further confirmed that YAP overexpression
could reduce DEM-induced inhibition of cell proliferation (Fig-
ure 3F). In summary, the oxidant-induced inhibition of GABP
is accompanied by a downregulation of YAP, and the restora-
tion of YAP substantially ameliorates oxidant-induced cell-
cycle arrest and apoptosis. These results strongly support
the hypothesis that YAP is an important downstream effector
of GABP.
The Mst1/Mst2 Double-Knockout Liver Exhibits
Increased Expression of YAP
Inactivation of theHippo signaling pathway in the liver by the dual
inactivation of Mst1 and Mst2 results in increased YAP protein
levels (Zhou et al., 2009). Although this increase most likely re-
flects, in part, a reduction in YAP degradation, the qPCR analysis
in this study showed that YAP mRNA is increased 2- to 3-fold in
Mst1/Mst2 double-knockout (DKO) livers (Figure 4A). We exam-
ined whether this increase in YAP mRNA involves the activation
of GABP. Lysates prepared from the livers of 6-week-old and
4-month-old wild-type (WT) or Mst1/Mst2 DKO mice were
analyzed by immunoblotting (Figure 4B). The livers from
6-week-old Mst1/Mst2 DKO mice were hyperplastic but non-
tumorous, whereas the livers from 4-month-old Mst1/Mst2
DKO mice contained multiple foci of hepatocellular carcinoma
(HCC) and tumors of mixed HCC and cholangiocarcinoma cellu-
larity (Zhou et al., 2009).
Phospho-Mob and phospho-YAP levels were previously
demonstrated to be dramatically reduced in tissues from Mst1/
Mst2 DKO mice (Zhou et al., 2009). We found that the GABPa
protein level was increased in all DKO samples, whereas the
GABPb level was increased only in 4-month-old DKO livers (Fig-
ure 4B). The increased expression of YAP and GABP subunits in
Mst1/Mst2 DKO livers was confirmed by immunohistochemistry
(IHC; Figure 4C). YAP expression in theWT liver was evident pre-
dominantly in the periportal area and in cells lining the bile ducts.
GABPb1 showed a similar distribution, whereas GABPa expres-
sion was more diffuse. In the Mst1/Mst2 DKO liver, the expres-
sion of all three proteins was widespread, greatly enhanced,
and strongly intranuclear.
In a reciprocal manner, the stable expression of Mst1 in an
HCC cell line derived from the Mst1/Mst2 DKO liver resulted in
a significant reduction in the expression of the YAP1 protein,
but the levels of the GABPwere not altered (Figure 4D). The tran-
scriptional activity of the Yap promoter-driven luciferase reporter
plasmids was also strongly reduced by the expression of Mst1
(Figure 4E). The effects of Mst1 restoration in the Mst1/2 DKO
HCC cell line were the opposite of the effects of the dual deletion
of liver Mst1 and Mst2, except that the restoration of Mst1 in the
HCC cell reduced GABP transcriptional activity without altering
the expression level of the GABP subunits. Nevertheless, we
next investigated the mechanism by which Hippo signaling sup-
presses GABP activity.
Figure 3. GSH Depletion Inhibits GABP-Dependent YAP Expression and its Impact on Cell Proliferation and Death
(A and B) GABP-mediated Yap promoter-driven luciferase activity (A) is inhibited by DEM treatment and restored by NAC addition. DEM treatment decreases
GSH levels (B). Error bars represent the SD; n = 3. **p < 0.01. The p values refer to comparisons between treatments with and without DEM.
(C) YAP, Skp2, and cMyc protein levels in HepG2 cells are inhibited by DEM treatment and restored by NAC addition.
(D) Immunofluorescence staining shows that DEM treatment increases the cytoplasmic retention of GABPa in HepG2 cells.
(E and F) Cell-cycle arrest and cell apoptosis resulting from the DEM treatment can be rescued or prevented by the overexpression of YAP, as shown by flow
cytometry analyseswith Annexin V/DAPI staining or BrdU/DAPI staining (E) andMTT cell proliferation assays (F). Error bars represent the SD; n = 3. **p < 0.01. The
p values refer to comparisons between DEM plus YAP-GFP and DEM plus GFP transfections.
The data are representative of at least three independent experiments. See also Figure S3.Lats1 Binds to and Promotes the Phosphorylation of
GABPb, Inhibiting the Homodimerization and Nuclear
Localization of GABPb
We performed coimmunoprecipitation assays to determine
whether Flag-tagged plasmids that express components of
the Hippo pathway, including Lats1, Mst2, Mob1, WW45, andCYAP, can bind specifically to Myc-GABPa or Myc-GABPb.
Indeed, both Flag-Lats1 and Flag-WW45 associated with
Myc-GABPb1L but not with Myc-GABPa (Figure 5A). In addi-
tion, endogenous Lats1 was coprecipitated with GABPb1
from WT liver extracts (Figure 5B). Cell fractionation experi-
ments showed that the transfection of Mst2, Lats1, or bothell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authors 1669
Figure 4. Mst1/Mst2 DKO Cells Exhibit
Enhanced Expression of the Yap Gene and
Increased GABP Activity
(A) qPCR analysis of YAP mRNA in WT and Mst1/
Mst2 DKO liver. Error bars represent the SD; n = 5.
**p < 0.01.
(B) Liver tissues from WT andMst1stMst2F/F Alb-
Cre mice (normal or HCC tissues) were analyzed
by immunoblotting with the indicated antibodies.
(C) IHC analysis of GABPa, GABPb1, or
YAP expression in liver tissue from WT and
Mst1/Mst2F/F Alb-Cre mice. The deletion of
Mst1/2 increases the expression levels of GABPa,
GABPb1, and YAP.
(D) The reconstitution of Mst1 reduces YAP
expression in HCC1 cells.
(E) The reconstitution of Mst1 reduces Yap pro-
moter-driven luciferase activity in HCC1 cells.
Error bars represent the SD; n = 3. *p < 0.05;
**p < 0.01.Mst2 and Lats1 into HeLa cells reduced the nuclear levels
of endogenous GABP1a and GABP1b and increased their
cytoplasmic levels (Figure S4A). This result was confirmed
by immunofluorescence staining of GABPa and GABPb
(Figure 5C).
Interestingly, although Mst2 does not directly bind to
GABPb1L, the overexpression of Mst2 alone also resulted in
the redistribution of GABPa/GABPb1, suggesting that this redis-
tribution may result from the activation of the kinase activity of
Lats (Figure S4B). Furthermore, the overexpression of Mst2 or
Lats1 resulted in the disappearance of the condensed bright
cytoplasmic dots of GABPb1 (Figures 5C and S4B). We specu-
late that this disappearance reflects an Mst2/Lats-induced1670 Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authorsdisruption of GABPb1 cytoplasmic
homodimers, which are formed via the
GABPb1 C-terminal leucine zipper-like
domain. Also, the overexpression of
Mst2/Lats1 reduced the homodimeriza-
tion of GABPb1 but did not affect the
association of GABPa with GABPb1
(Figure 5D).
When expressed alone, GABPa does
not exhibit preferential nuclear localiza-
tion but relies on the GABPb nuclear
localization sequence (NLS, aa 243–319)
for nuclear entry (Sawa et al., 1996).
Using GFP-tagged GABPb fragments,
we demonstrated that the binding site
on GABPb for Flag-Lats1 is located
between amino acids 241 and 319, which
contain the NLS (Figure S4C). Thus, the
binding of Lats1 to GABPb may directly
interfere with the ability of the heterodi-
meric GABP to enter the nucleus.
Previous work has shown that Ser170
and Thr180 of GABPb can be phosphory-
lated directly by MAPKs (Flory et al.,
1996; Fromm and Burden, 2001). There-fore, we examined whether GABPb phosphorylation regulates
GABP nuclear localization. An in vitro kinase assay showed
that Lats1 itself can phosphorylate GABPb, but not GABPa (Fig-
ure 5E). Among the Myc-tagged GABPb fragments that are
overexpressed in 293T cells (1-166, 1-260, and 260-383), only
GABPb(1-260) resulted in an upshifted band (Figure 5F), sug-
gesting that GABPb(1-260) may be phosphorylated. Consistent
with this idea, cotransfection of Myc-tagged GABPb(1-260)
with Mst2/Lats1 increased the relative abundance of the
slower-migrating GABPb(1-260) band (Figure 5G). To determine
whether the phosphorylation of Ser170 or Thr180, or both, is
responsible for the upshifted GABPb(1-260) band, we con-
structed S170A, T180A, or S170A/T180A mutant GABPb(1-260)
Figure 5. Lats1 Phosphorylates GABPb1 and Regulates GABP Cytoplasmic Retention in HepG2 Cells
(A) Lats1 and WW45 interact physically with GABPb1 but not with GABPa, as shown by pull-down assays.
(B) Endogenous Lats1 was coimmunoprecipitated with GABPb1 from WT liver lysates.
(C) Overexpression of Lats1 increases the cytoplasmic retention of GABPa or GABPb1, as shown by immunofluorescence staining.
(D) Mst2 or Lats1 regulates GABPb1L dimerization. 293T cells were transfected with GFP-GABPa, GFP-GABPb1L, Myc-GABPb1L, or Myc-Mst2/Lats1 using the
indicated combinations, and the dimerization of the GABP subunits was determined.
(E) Lats1 kinase phosphorylates GABPb1 in vitro. An in vitro kinase assay was performed using GST-GABPa or GABPb1L recombinant protein and Flag-Lats1
kinase.
(F and G) Domain-deletion mutants of GABPb1L were expressed in HepG2 cells. GABPb1L(1-260) fragments exhibit two bands (F). Mst2/Lats1 enhances the
upshifted band of WT GABPb1L(1-260) fragments. The GABPb1L mutant S170A, but not S180A, abolishes this upshift (G).
(H) Mst2/Lats1 promotes the interaction of GABPb1 with 14-3-3 via phosphorylation of Ser170. The mutant GABPb1L(1-260) S170A abolishes this interaction.
(I) Mst2/Lats1 inhibits GABPa/b-driven YAP2600-Luc luciferase activity. This inhibition is abolished with the mutant GABPb1L(S170A). Error bars represent SD;
n = 3. **p < 0.01.
The data are representative of at least three independent experiments. See also Figure S4.expression plasmids and cotransfected them with Mst2/
Lats1. The S170A and S170A/S180A GABPb(1-260) mutants,
but not GABPb(1-260) T180A, lost the slower-migratingCGABPb(1-260) band, indicating that the phosphorylation of
Ser170 is responsible for the upshifted band of GABPb(1-260)
(Figure 5G).ell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authors 1671
Furthermore, cotransfection with Mst2/Lats1 not only
enhanced the abundance of the upshifted band (Figure 5G) but
also strongly stimulated the association of GABPb with 14-3-3,
which did not occur with the GABPb Ser170Amutant (Figure 5H,
second panel from bottom). Binding to 14-3-3 promotes the
nuclear exit of the protein that is complexed with 14-3-3, as
demonstrated for phospho-YAP (Zhao et al., 2007). Thus,
Lats1 can bind to the NLS-encompassing region of GABPb,
interfering with GABPb nuclear translocation. In addition, Lats1
can promote the phosphorylation of GABPb Ser170, thereby
promoting its association with 14-3-3 and favoring the nuclear
exit of GABP. Finally, our results demonstrate that the coexpres-
sion of Mst2/Lats1 with GABPa/GABPb1L strongly inhibits
YAP2600-Luc luciferase activity, and that this inhibition is
completely abolished upon cotransfection of Mst2/Lats1 with a
GABPa/GABPb1L(S170A) mutant protein (Figure 5I). These re-
sults suggest that the Hippo signaling pathway suppresses
GABP transcriptional activity via a mechanism that depends on
the phosphorylation status of GABPb Ser170.
Acetaminophen-Induced Hepatotoxicity Involves GABP
Inactivation and YAP Depletion
We found that theGSH/GSSG ratio was significantly increased in
the Mst1/Mst2 DKO liver (Figure S5A). Consistent with this
observation, the levels of several enzymes that promote the
accumulation of GSH, such as GSH reductase (GSR) and the
modifying subunit (GCLM) of the g-glutamyl-cysteine ligase cat-
alytic subunit (GCLC), and several antioxidant proteins, including
NAD(P)H:quinone oxidoreductase (NQO1), cytosolic thioredoxin
(Txn1), and mitochondrial thioredoxin (Txn2), were all increased
in Mst1/Mst2-deficient liver tissue relative to the WT liver (Fig-
ure S5B). Thus, the observed GABP activation and increase in
YAP mRNA levels in the Mst1/2 DKO liver may be partially due
to the increased GSH/GSSG ratio and reduced GABP oxidation.
The administration of acetaminophen (N-acetyl-p-amino-
phenol [APAP], 300 mg/kg) to C57Bl/6 mice depleted the GSH
in the liver and resulted in hepatocellular necrosis, as indicated
by the increased plasma activities of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST; Henderson et al.,
2000). After oral administration of APAP, the levels of YAP and
Skp2 in the livers of WT mice were reduced within 6 hr and
were barely detectable after 12 hr (Figure 6A). Although the
GABPa and GABPbmRNA levels were unaffected by APAP (Fig-
ure 6B), the GABPa and GABPb protein levels were decreased
by 12 hr after APAP treatment (Figure 6A). The YAP mRNA level
was also dramatically reduced at this time point (Figure 6B).
Interestingly, the livers of Mst1/Mst2 DKO mice, in which YAP
is underphosphorylated and overexpressed, were protected
from APAP-induced hepatotoxicity. Compared with WT, the
APAP-induced increase in plasma ALT and AST (Figure 6C)
was dramatically reduced in the livers of Mst1/2 DKO mice. His-
tological examination confirmed that the hepatic necrosis
caused by APAP treatment in WTmice (Figure 6D, left) was virtu-
ally eliminated in the Mst1/2 DKO mice (Figure 6D, middle).
We assessed the importance of YAP overexpression for APAP
resistance in Mst1/2 DKO mice using transgenic mice with
constitutively nuclear expression of YAP(Ser127Ala) in their liver.
These mice also exhibited substantial protection from APAP-1672 Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authorsinduced hepatic necrosis, as shown by histology (Figure 6D,
right) and plasma ALT/AST levels (Figure 6E). The hypothesis
that both direct APAP-induced tissue damage and APAP-
induced depletion of YAP contribute to APAP-hepatotoxicity is
supported by the observation that liver-specific inactivation of
YAP itself resulted in areas of spontaneous liver necrosis as early
as 4 weeks of age (Figure 6F, top). These areas of necrosis
became much more severe by 8 weeks (Figure 6F, bottom)
and were accompanied by increased levels of plasma ALT and
AST activity compared with the WT littermates (Figure S5C).
Interestingly, YAP knockout livers exhibited a decreased GSH/
GSSG ratio, which may have contributed to the progressive
cellular damage, whereas the GSH/GSSG ratio was increased
in YAP transgenic livers (Figure S5D). Hepatic extracts of WT,
Yap+/, and Yap/ mice were immunoblotted for a variety of
antioxidant regulators and proteins involved in mitochondrial
biogenesis.
The results demonstrated (Figure S5E) that YAP dele-
tion significantly reduced the expression of ATP1b1, TYMS,
COX5b, Tfam2, TXN2, Sp1, SOD2, SOD3, PRDX1, NQO1, and
GSR. Conversely, YAP overexpression in HepG2 cells greatly
increased the luciferase activity driven by promoters of the anti-
oxidant Txn2 or Nqo-1 genes, whereas Mst2/Lats1 modestly
suppressed the expression of these reporters (Figure S5F).
Thus, YAP deficiency reduces the expression of a variety of
genes that encode mitochondrial proteins and proteins with
antioxidant properties, resulting in increased cellular reactive
oxygen species (ROS) and a diminished GSH/GSSG ratio.
We determined the survival of WT, Mst1/2 liver DKO, YAP liver
null, and YAP liver-transgenic mice treated with a near-lethal
dose of APAP (300 mg/kg; Figure 6G). Consistent with previous
observations, 50% of WT mice died within 9 hr, and another
30% died by 15 hr after oral administration of APAP. All mice
with liver-specific deletions of YAP were dead within 7 hr. In
contrast, Mst1/2 liver DKO mice were completely resistant to
APAP-induced death, and only 20% of YAP liver-transgenic
mice died within 15 hr of APAP treatment (Figure 6G). We also
treated mice that had received adenovirus-encoded GFP or
GFP-GABPa+b with APAP (300 mg/kg). The mice overexpress-
ing GABPa+b showed modest protection from APAP-induced
death (Figure 6H). Thus, GABPa+b or YAP overexpression, via
antiapoptotic and antioxidant defense mechanisms, protects
against APAP-induced liver damage. We conclude that the
decrease in YAP levels after APAP treatment is partly due to
APAP-induced inhibition of GABP and is an important contrib-
utor to APAP-induced hepatic necrosis.
Loss of Hippo Signaling Is Correlated with the Increased
Nuclear Localization of GABP and YAP in Human Liver
Cancers
An increase in YAP expression and signaling is the essential pre-
cursor for the development of HCC in Mst1/2 liver DKO mice
(Zhou et al., 2009). Our results demonstrate that enhanced
GABP expression/activity contributes to the increased YAP
levels observed in this model. Previous studies have shown
that Hippo signaling is commonly lost in human HCCs, as shown
by the loss of the cleaved active Mst1 catalytic fragments and
decreased levels of pYAP and pMob1 (Zhou et al., 2009), and
Figure 6. GABP-Dependent YAP Expression Is Responsible for APAP-Induced Hepatotoxicity
(A and B) APAP administration decreases YAP expression. At the indicated times after APAP administration (300 mg/kg), the levels of YAP, p-YAP, Skp2, P21,
GABPa, and GABPb1proteins in the liver were determined by immunoblotting with specific antibodies (A). The mRNA level of YAP, but not that of GABPa or
GABPb1, was decreased at 12 hr after APAP administration (B). Error bars represent the SD; n = 3. ***p < 0.001. The p values refer to comparisons of YAP mRNA
expression between 12 and 0 hr post-APAP treatment.
(C) The gradually increasing levels of the liver enzymes ALT and AST observed in the serum of WTmice after administration of APAP are almost absent inMst1/
Mst2F/F Alb-Cremice. Error bars represent the SD; n = 6. **p < 0.01; ***p < 0.001. The p values refer to comparisons between samples from WT and Mst1/Mst2
DKO mice.
(D) H&E staining shows that Mst1/2 liver DKO mice and liver-specific YAP transgenic mice exhibit less liver damage after APAP treatment compared with
WT mice.
(E) Compared with WT mice, liver-specific YAP transgenic mice have lower levels of ALT and AST in the serum after APAP treatment (300 mg/kg). Error bars
represent the SD; n = 6. **p < 0.01; ***p < 0.001. The p values refer to comparisons between samples of WT and YAP transgenic mice.
(F) Four-week-old (top) and 8-week-old (bottom) liver-specific YAP knockout mice spontaneously exhibit cell necrosis in livers.
(G) Kaplan-Meier survival curves for WT, Mst1/2 liver DKO, liver-specific YAP(S127A) transgenic, and YAP liver knockout mice over 36 hr after a single toxic dose
of APAP (300 mg/kg).
(H) Kaplan-Meier survival curves over 36 hr for WT mice injected with adenovirus-encoded GABPa and GABPb or empty vector after a single toxic dose of APAP
treatment (300 mg/kg).
See also Figure S5.
Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authors 1673
our current results demonstrate that Hippo signaling inhibits
GABP activity (Figure 5). Therefore, we inquired whether GABP
activity or expression is upregulated in human HCC.
We examined liver-derived tumorous and nontumorous tis-
sues from50Chinese patientswith liver cancer. IHCof the non-
tumorous regions of human liver showed that staining for YAP,
GABPa and GABPb was the most intense in cells surrounding
the bile ducts. In the HCCs, the total YAP stainingwas enhanced,
and YAP nuclear staining was more prevalent than in nontumo-
rous regions. In normal livers, GABPa showed a more wide-
spread distribution than YAP, whereas GABPb staining showed
periportal and nuclear localization similar to that observed for
YAP. In human HCCs, GABPa and GABPb staining was greatly
intensified in the nucleus compared with that observed in the
adjacent nontumorous liver. The expression of YAP, GABPa, or
GABPb was also estimated by immunoblotting analysis and
real-time PCR. The relative expression levels of YAP, GABPa,
or GABPbwere all significantly higher in human HCCs compared
with nontumorous livers (Figures 7D–7F and S6). Consistent with
a previous result (Zhou et al., 2009), the inactivation of the Hippo
signaling pathway was also evident in most liver cancer speci-
mens, as indicated by the diminished levels of pMob (T35) and
pLats1 (S909; Figures 7D, 7E, and S6). These results suggest
that the enhanced expression of YAP in human HCC results in
part from the activation of GABP, and that similar to the case
with Mst1/2 DKO mouse liver, the increased YAP expression is
due in part to inactivation of the Hippo signaling pathway.
DISCUSSION
GABP is a heteromeric transcription factor that binds to a GA-
rich EBS (GGAAG) in DNA and comprises two unrelated sub-
units: GABPa, a member of the Ets family, and GABPb, a
Notch-Ankyrin repeat protein (Rosmarin et al., 2004). The Yap
promoter region (3,300 bp to + 207 ATG site) contains 16
EBSs. However, among the 18 Ets family proteins studied, only
the GABP heterodimer significantly activated transcription from
the YAP promoter. These observations, together with the pres-
ence of GABP on the Yap promoter in HeLa cells and primary
mouse hepatocytes, strongly support the physiological rele-
vance of GABP regulation of YAP transcription.
The GABP transcription factor has been linked to the regula-
tion of diverse functional classes of genes, includingmany genes
that encode key cell-cycle control proteins (Yang et al., 2007).
The depletion of either the GABPa or GABPb subunit results in
a reduction of YAP mRNA, G1/S cell-cycle blocking, and
increased cell death. These cell-fate outcomes are substantially
rescued by restoring YAP expression. Thus, GABP is required for
the expression of YAP, and YAP is an important downstream
effector of GABP for cell proliferation and survival. The ability
of adenovirus-encoded GABP to promote hepatocyte prolifera-
tion in vivo, and the increased abundance of GABP and YAP
within 24 hr after a partial hepatectomy support the idea that
GABP-induced YAP expression contributes to posthepatectomy
liver regeneration.
In addition to identifying GABP as a critical regulator of YAP
expression, we provide evidence that the transcriptional activ-
ities of YAP and GABP are negatively regulated by the Hippo1674 Cell Reports 3, 1663–1677, May 30, 2013 ª2013 The Authorssignaling pathway. As a result, the deletion of Mst1 and Mst2
from the mouse liver is accompanied by an increase in the
YAP mRNA level. Conversely, the reconstitution of Mst1 expres-
sion in an HCC cell line derived from the Mst1/2 DKO liver
strongly suppresses the GABP-dependent transcriptional activ-
ity of the Yap promoter without altering GABPa/b1 expression.
Various mechanisms appear to be involved in the Mst1/Mst2-
mediated inhibition of GABP activity. Lats1, the inhibitory YAP
kinase of the canonical Hippo pathway, can bind directly to
GABPb1 at a segment contiguous with the GABPb1 NLS
domain, thereby interfering with GABP nuclear translocation.
Binding of Lats1 to GABPb1 also disrupts GABPb1 homodimeri-
zation, thereby inhibiting the tetramerization of the GABPa/
GABPb dimers, which is important for optimal GABP transcrip-
tional activity. Whether Lats1 binding modulates the interaction
of GABPwith its cotranscriptional modulators remains unknown.
The Hippo pathway also inhibits GABP through GABPb1 phos-
phorylation. The overexpression of Mst2/Lats1 stimulates the
phosphorylation of GABPb1(Ser170), GABPb1 binding to 14-
3-3, and GABP nuclear exit.
Previous studies have shown that both subunits of GABP
(Thr280 of GABPa, and Ser170 and Thr180 of GABPb) can be
directly phosphorylated by the MAPKs ERK (Flory et al., 1996)
and SAPK/JNK (Hoffmeyer et al., 1998) in response to exposure
to serum, active phorbol esters, UV light, and methyl methane
sulfonate, which strongly induce the SAPK/JNK and p38 kinases
(Wasylyk et al., 1998). The overexpression of Mst2 can activate
SAPK/JNK (Ura et al., 2007), and TAO kinase, whichwas recently
shown to operate as a direct upstream activator of Hippo kinase,
can activate the SAPK/JNK and p38 kinases in certain situations
(Boggiano et al., 2011; Poon et al., 2011). The identity of the
GABPb (Ser170) protein kinases that are regulated by the Hippo
pathway in vivo remain to be elucidated. We observed that Lats1
itself can phosphorylate GABPb but not GABPa in vitro, but the
functional significance of this modification is not yet known.
A third mechanism by which Hippo signaling can inhibit GABP
transcriptional activity involves the ability of Mst1/Mst2 tomodify
the GSH/GSSG ratio in a manner that is unfavorable to GABP
transcriptional activity. The elimination of Mst1/Mst2 from the
liver is accompanied by an increase in the GSH/GSSH ratio,
due in part to the increased expression of a cohort of enzymes
that promote GSH synthesis and the scavenging of oxidants.
The restoration of Mst1 reverses this response and reduces
the GSH/GSSG ratio. Thus, Hippo signaling may promote the
oxidative inactivation of GABP. The increase in GSH/GSSG in
the Mst1/Mst2 DKO livers appears to be mediated by the
increased YAP activity (Figure 6J). Similarly, Yki was recently
reported to reduce ROS inDrosophila by upregulating mitochon-
drial function and enhancing antioxidant expression (Nagaraj
et al., 2012). However, the results of studies on the effects Hippo
signaling on ROS production (Abdollahpour et al., 2012; Choi
et al., 2009) and the effects of ROS on Hippo signaling (Lehtinen
et al., 2006; Ohsawa et al., 2012) are conflicting and do not allow
a general conclusion to be drawn.
In contrast, the importance of GSH depletion on the hepatic
toxicity of APAP (Tylenol) is very well established. Overdose of
APAP causes severe GSH depletion, ROS generation, and
serious liver injury, and may even result in death (Henderson
Figure 7. Loss of Hippo Signaling Is Correlated with Increased Nuclear Localization of GABP and YAP in Human Liver Cancers
(A–C) IHC analysis of YAP1 (A), GABPa (B), and GABPb1 (C) in tissue sections of nontumorous livers (Normal) or liver cancers (Tumor) isolated from one patient.
Greater expression levels of YAP1, GABPa, and GABPb1 are found in the biductal areas of normal livers and in all liver cancer cells.
(D and E) The expression levels of YAP, GABPa, and GABPb are significantly increased in liver cancer (T) compared with the nontumorous liver tissue (N) isolated
from one patient. Seven representative paired samples analyzed by immunoblotting with the indicated antibodies are shown (D). See also Figure S5 for the
remaining 42 paired samples. The intensities of the immunoblot bands were quantified with the use of Imagine gel software (E).
(F) ThemRNA levels of GABPa, GABPb1, and YAPwere quantified by qPCR, and the ratio of the relativemRNA expression in nontumorous liver tissue (N) and liver
cancer tissue (T) from one patient was plotted. Error bars represent the SD.
(G) A proposed working model for how the Hippo signaling pathway regulates cell growth and antioxidant defenses via modulation of GABP activity. The Hippo
pathway kinase, Lats1, binds to GABPb1 at the nuclear localization sequence (aa 241–319) and phosphorylates GABPb1 on Ser170, which disrupts the
homodimerization of GABPb1/b1 and promotes GABPb1/14-3-3 association, resulting in the exit of GABP from the nucleus and termination of its transcriptional
activation. The heterodimerization of GABPa/b1 can also be inhibited by depletion of GSH. Hippo (Mst1/2)-Wts (Lats1/2) signaling reduces theGSH/GSSG ratio in
the liver, thereby suppressing GABP activity. Upon the loss of Hippo signaling, GABP translocates to the nucleus, where it activates the expression of a set of
genes, including YAP. YAP is essential for several cellular and tissue responses against oxidative stress, including increases in NOQ-1, TXN1.2, and other
antioxidant regulators. Overactive YAP can also cooperate with TEAD to promote organ growth and tumorigenesis, including the development of HCC.
See also Figure S6.
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et al., 2000). In this study, we have shown that an APAP overdose
inhibits GABP transcriptional output and leads to a profound
depletion of YAP within 12 hr of treatment. Moreover, the YAP
deficiency greatly sensitizes mice to APAP hepatotoxicity due
to a marked decrease in the expression of mitochondrial and
antioxidant genes, and the restoration of active YAP markedly
ameliorates APAP hepatotoxicity. However, harnessing the
proliferative and antiapoptotic functions of YAP for the treat-
ment of APAP-overdose-induced liver failure is a daunting chal-
lenge in view of the oncogenic function of YAP in human liver
cancers.
As shown by the decreased levels of phospho-YAP andMob1,
Hippo signaling is frequently lost in human HCCs (Zhou et al.,
2009). In view of the current data showing that the loss of Hippo
signaling restores GABP transcriptional activity and enhances
YAPmRNA abundance, GABP emerges as a potential therapeu-
tic target in human HCCs and in other cancers driven by YAP.EXPERIMENTAL PROCEDURES
Animals
Mst1, Mst2, or Yap gene conditional knockout or transgenic mice have been
previously described (Camargo et al., 2007; Zhou et al., 2009). WT C57BL/6
mice were originally purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). All mice were maintained under specific pathogen-free conditions
at Xiamen University Laboratory Animal Center (XMULAC). Mouse work was
conducted with the approval of the Institutional Animal Care and Use Commit-
tee and in strict accordance with good animal practice as defined by XMULAC.
APAP-Induced Hepatotoxicity
Mice were administered APAP (Sigma, St. Louis, MO, USA) via oral gavage af-
ter 12 hr of starvation. APAPwas used at a concentration of 300mg/kg in PBS.
To assess the injurious effects of APAP on liver histology and function, serum
was collected frommice via cardiac puncture. Serum samples were taken at 3,
6, and 12 hr after gavage. ALT and AST levels were determined in blood spec-
imens with the use of an ALT/AST assay kit (20030106; NJJCBio, Beijing,
China). For histopathology, the dissected liver tissues were fixed in buffered
formalin, embedded in paraffin, and then processed for tissue-section staining
with hematoxylin and eosin (H&E).
Human Liver and HCC Samples
Human samples were obtained under informed consent from the human tissue
banks of Xiamen Hospital of Traditional Chinese Medicine and Zhongshan
Hospital of Xiamen University. All experiments were performed with the
approval of the Xiamen University Review Board. Snap-frozen biopsies from
specimens of normal liver tissue (distant from the tumor) and HCC were
collected. The diagnosis of HCC or normal liver was confirmed based on
histological findings by independent pathologists.
Statistical Analyses
The data are representative of at least three independent experiments. Error
bars represent SD, n R 3. Student’s t test (two-tailed) was used to assess
the differences between means for all data analyzed. Tests with a p value of
<0.05 were considered statistically significant.
For further details regarding the materials and methods used in this work,
see the Extended Experimental Procedures.SUPPLEMENTAL INFORMATION
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